| Gilead Terminates Cicletanine Trial; All Eyes Remain on Quad | | Gilead Sciences Inc., of Foster City, CA, has terminated a Phase II trial of cicletanine for pulmonary arterial hypertension (PAH) due to failure of the trial to meet its primary endpoint of improvement in exercise capacity. Gilead acquired cicletanine from Navitas Assets LLC in 2008. Find out the details. |  |
| Health Care & Policy |  |  | | - Immunogen-Roche breast cancer drug meets main goal in trial
Roche Holding and ImmunoGen said their antibody drug T-DM1, or trastuzumab emtansine, met the primary goal of a late-stage trial by significantly extending the lives of women with HER-2 positive metastatic breast cancer compared with a combination of two standard treatments. Roche's Genentech unit has submitted the drug for FDA review and will soon file a marketing application with European regulators. CBS News/The Associated Press (8/27), Reuters (8/27)        | Earn 2X rewards points on shipping costs with The Business Gold Rewards Card from American Express OPEN. Designed to earn Membership Rewards® points faster:
• 3X points on airfare
• 2X points on advertising, gas, and shipping
• 1X points on everything else
LEARN MORE AND APPLY |
  | Company & Financial News | | | | - Alder receives $3.5M from Bristol for Crohn's drug trial
Bristol-Myers Squibb paid Alder Biopharmaceuticals a $3.5 million milestone fee for initiating a midstage study of rheumatoid arthritis drug candidate ALD518, or BMS-945429, in patients with Crohn's disease. The trial, which will involve 288 patients, is expected to be finished in November 2015. Xconomy/Seattle (8/27) | Global Developments | | | | - Australian project will look for mutations that cause melanoma
Australian researchers began a two-year project designed to identify common genetic mutations associated with melanoma and to find new ways of detecting and treating the disease based on the genetic characteristics of individual melanomas. The $5.7 million initiative, called the Australian Melanoma Genome Project, will involve researchers from the Melanoma Institute Australia and hospitals, universities and institutes in the country. The project "will lead to better diagnostic tests and new drugs which can specifically target the mutations that are causing this particular cancer," said John Thompson, Melanoma Institute Australia's executive director. GenomeWeb Daily News (free registration) (8/24) - Researchers grow lung cells for drug testing
Canadian researchers have succeeded in producing lung cells from stem cells derived from the skin of patients with cystic fibrosis, according to a study published in the journal Nature Biotechnology. The cells could be used in the testing of medicines and potentially the individualization of treatment as well as the regeneration of lung tissue. CTV.ca (Canada)/The Canadian Press (8/26)
| Food & Agriculture | | | | - Monsanto's biotech soybean could enter Argentine market next year
Monsanto plans to start marketing its new insect- and glyphosate-resistant soybean seed Intacta RR2 in Argentina late next year. The plan is contingent on reaching a seed royalty deal with growers, suppliers and exporters, said Pablo Vaquero, Monsanto's director of sustainability and corporate affairs for Latin America south. The nation is developing regulations to patent rights. Fox Business/Dow Jones Newswires (8/24) | Industrial & Environmental | | | | - BIO, others rebut claims RFS waiver would boost corn availability
BIO and other members of the Biofuels Producers Coordinating Council wrote a letter to President Barack Obama contesting claims that a Renewable Fuel Standard waiver would increase corn availability. Built-in mechanisms in the RFS are already "working to minimize the consumer impact of lower grain yields," the groups said. Tampering with the RFS would drive up fuel costs, draw investments away from advanced biofuels and hurt the economy, they added. The Hill/E2 Wire blog (8/27), Platts (8/27) | News from BIO | | | | - BIOtechNOW
BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter.
| SmartQuote | | | |  | It is better to fail in originality than to succeed in imitation."
--Herman Melville,
American writer and poet  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Monday, August 27, 2012
- Friday, August 24, 2012
- Thursday, August 23, 2012
- Wednesday, August 22, 2012
- Tuesday, August 21, 2012
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2012 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment